FDA clears test for determining tumor origin

September 2008
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p32
The article announces that the U.S. Food and Drug Administration (FDA) cleared the Pathwork Tissue of Origin test from Pathwork Diagnostics Inc. for marketing. The test measures gene expression patterns and compares them with a database of known tumor types to determine the tumor's origin. It is the second in vitro diagnostic multivariate index assay cleared by the FDA.


Related Articles

  • Medicare Covers the Pathwork(r) Tissue of Origin Test: Helps Diagnose Metastatic and Other Difficult to Diagnose Cancers.  // Biomedical Market Newsletter;6/19/2011, p874 

    The article reports on the positive coverage policy issued by the Palmetto GBA LLC for the Pathwork® Tissue of Origin Test by Pathwork Diagnostics Inc It states that decision of Palmetto entails that the test will be covered for Medicare patients throughout the U.S. It says that the Pathwork...

  • Intermountain Healthcare Establishes Reimbursement Coverage Policy for Pathwork Diagnostics' Tissue of Origin Test.  // Biomedical Market Newsletter;5/17/2011, p510 

    The article reports that the Tissue of Origin Test of Pathwork Diagnostics Inc. will be under the reimbursement coverage policy of SelectHealth, a branch health insurance of Intermountain Healthcare. Pathwork Diagnostics' chief executive officer (CEO) Deborah J. Neff says that the test is the...

  • GENE TESTING OF FLUID SPECIMENS IDENTIFIES CANCER ORIGEN.  // Biotech Business;Apr2011, Vol. 24 Issue 4, p6 

    The article deals with the results of a study on Pathwork Diagnostics Incorporated's Tissue of Origin Test for various formalin-fixed, paraffin-embedded (FFPE) fluid specimens conducted in the U.S. The molecular test assists in determining the origin of metastatic tumors accurately. It measures...

  • Pathwork gains approval for its new Tissue of Origin test. FORD, OMAR // Medical Device Daily;6/16/2010, Vol. 14 Issue 115, p1 

    The article reports on the approval received by Pathwork Diagnostics from the U.S. Food and Drug Administration (FDA) for its Tissue of Origin test, a test kit which can be used and interpreted in a hospital setting and designed to help physicians and patients in interpreting tissue tests. The...

  • Gene testing of fluid specimens helps identify cancer origin. PEDERSEN, AMANDA // Medical Device Daily;3/1/2011, Vol. 15 Issue 40, p1 

    The article discusses Pathwork Diagnostics' Tissue of Origin test that will be presented in March 2011 at the 100th annual meeting of the United States and Canadian Academy of Pathology. The purpose of the test is to measure the gene expression levels in roughly 2,000 genes. The test, which was...

  • Pathwork study shows test can impact cancer treatment. Ford, Omar // Medical Device Daily;1/10/2012, Vol. 16 Issue 6, p1 

    The article reports on a study which revealed that using the Pathwork Tissue of Origin Test from Pathwork Diagnostics can significantly alter clinical practice patterns for the treatment of metastatic cancer. The Pathwork Tissue of Origin Test help pathologists and oncologists diagnose...

  • FDA approves Aixplorer for novel cancer diagnostics. BROSKY, JOHN // Medical Device Daily;8/27/2009, Vol. 13 Issue 165, p1 

    The article reports on the 510(k) approval granted by the U.S. Food & Drug Administration (FDA) to SuperSonic Imagine for Aixplorer, an ultrasound system for detecting and characterizing tumors to facilitate screenings for breast and prostate cancers. The diagnostic tool combines a high-end...

  • AUTOMATED BREAST ULTRASOUND. Hardy, Kathy // Radiology Today;Dec2012, Vol. 13 Issue 12, p30 

    The article discusses the U-Systems' somo-v Automated Breast Ultrasound System (ABUS), a new diagnostic tool recently approved by the FDA for breast cancer screening in asymptomatic women with dense breast tissue. Maria Lander, director of breast imaging at the Comprehensive Cancer Center at...

  • Pathwork's test to ID tumor types validated in large study. YOFFEE, LYNN // Medical Device Daily;4/1/2009, Vol. 13 Issue 61, p1 

    The article reports that a study has given strong validation to a test developed by Pathwork Diagnostics designed to help physicians reduce diagnostic uncertainty for tumors of uncertain origin. It was mentioned that the company's Pathwork Tissue of Origin Test uses a microarray to measure the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics